AWM
MLYS icon

Avior Wealth Management’s Mineralys Therapeutics MLYS Stock Holding History

Avior Wealth Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3
Closed -$38 – 3137
2024
Q1 		$38 Buy
+3
New +$37 ﹤0.01% 3552

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Avior Wealth Management's MLYS Position: Q2 2024 in Review

Avior Wealth Management sold out of Mineralys Therapeutics (MLYS) in Q2 2024, closing a stake of 3 shares — an estimated $38 sold.

Avior Wealth Management first reported a position in MLYS in Q1 2024 and held it in 1 quarter. The position peaked at $38 in Q1 2024. 94 funds tracked by Wall St. Rank hold MLYS as of Q2 2024.

  • Avior Wealth Management reported no remaining Mineralys Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 3 Mineralys Therapeutics shares in Q2 2024, an estimated $38.
  • Avior Wealth Management first reported a position in Mineralys Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Mineralys Therapeutics position peaked at $38 in Q1 2024.
  • 94 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.